Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP10 in Women Undergoing Cardiopulmonary Bypass
NCT00082121Phase 2Completed
- Sponsor
- Avant Immunotherapeutics, Inc.
- Start
- Apr 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of CDX-1135 in Myocardial ischemia (MI), coronary arteriosclerosis, aortic valve insufficiency (AI), mitral valve insufficiency (MR), sponsored by Avant Immunotherapeutics, Inc.. Started Apr 2004; status: completed.
02
Drugs
CDX-1135
03
Conditions
Myocardial ischemia (MI)coronary arteriosclerosisaortic valve insufficiency (AI)mitral valve insufficiency (MR)
Beyond the preview
Go deeper on NCT00082121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082121.